Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Adv Drug Deliv Rev. 2016 Nov 30;119:20–43. doi: 10.1016/j.addr.2016.11.003

Figure 7.

Figure 7

Antitumor efficacy following systemic delivery of guanidine-cyclodextrin-PEG-anisamide (G–CD–PEG–AA)-siVEGF complex evaluated by (a) tumor volume, (b) VEGF mRNA knockdown, and (c) body weight concurrent with tumor treatments. Liver enzyme levels, (d) aspartate aminotransferase (ASAT) and (e) alanine aminotransferase (ALAT) (mean ± SD shown; NS = no significance, *p < 0.05). Adapted from ref [228]